235. 副甲状腺機能低下症 ［臨床試験数：44，薬物数：59（DrugBank：18），標的遺伝子数：4，標的パスウェイ数：5］
Searched query = "Hypoparathyroidism", "Accessory thyroid hypergasia disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03878953 | March 30, 2020 | 4 November 2019 | A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism | A Phase 3, Open-label Clinical Study of rhPTH(1-84) Treatment in Japanese Subjects With Chronic Hypoparathyroidism | Chronic Hypoparathyroidism | Drug: rhPTH(1-84) | Shire | Not recruiting | 20 Years | 85 Years | All | 12 | Phase 3 | Japan | |
| 2 | NCT03425747 | September 1, 2019 | 26 August 2019 | Efficacy of Calcium Citrate Versus Calcium Carbonate in Maintaining Normal Serum Calcium Level and Changing Quality of Life in Patients With Chronic Hypoparathyroidism | CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM | Chronic Hypoparathyroidism | Drug: Calcium Carbonate;Drug: Calcium Citrate | Campus Bio-Medico University | Not recruiting | 18 Years | 75 Years | All | 22 | Phase 4 | ||
| 3 | NCT04126941 | June 1, 2019 | 28 October 2019 | Monocentric Study on the Use of Teriparatide in Children With hypoparathyroïdism | Bi-daily Injection of Subcutaneous Teriparatide in Children With Hypoparathyroidism: Single-center Experience | Hypoparathyroidism | Other: Serum calcium concentrations results | Hospices Civils de Lyon | Recruiting | 2 Years | 18 Years | All | 9 | N/A | France | |
| 4 | ChiCTR1900022194 | 2019-04-02 | 1 April 2019 | A prospective randomized controlled trial of different calcium supplementation regimens on the recovery of parathyroid function after thyroid surgery | A prospective randomized controlled trial of different calcium supplementation regimens on the recovery of parathyroid function after thyroid surgery | Hypoparathyroidism | Prophylactic group:Prophylactic calcium and vitamin D supplementation;treatment group:calcium and vitamin Dsupplementation is appropriate for hypocalcemia symptomatic patients; | West China Hospital, Sichuan University | Recruiting | 18 | 75 | Both | Prophylactic group:150;treatment group:150; | N/A | China | |
| 5 | NCT03364738 | September 26, 2018 | 11 June 2019 | Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism | An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects With Hypoparathyroidism | Hypoparathyroidism | Biological: rhPTH(1-84) | Shire | Not recruiting | 18 Years | N/A | All | 22 | Phase 3 | United States;Canada;Denmark;Hungary | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03516773 | June 17, 2018 | 8 April 2019 | Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism | An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Parathyroid Hormone [PTH (1-34)] and NATPARA® in Patients With Hypoparathyroidism | Hypoparathyroidism | Drug: EB612 (EBP05);Drug: NATPARA/NATPAR | Entera Bio Ltd. | Not recruiting | 18 Years | 80 Years | All | 20 | Phase 2 | Israel | |
| 7 | NCT03324880 | February 15, 2018 | 23 April 2019 | Study of the Effect of Recombinant Human Parathyroid Hormone [rhPTH(1-84)] on Symptoms Improvement and Metabolic Control Among Adults With Hypoparathyroidism | A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)] | Hypoparathyroidism | Biological: rhPTH(1-84);Biological: Placebo | Shire | Recruiting | 18 Years | 85 Years | All | 150 | Phase 4 | United States;Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom | |
| 8 | EUCTR2017-000284-32-SE | 18/01/2018 | 28 February 2019 | Symptom Improvement Evaluation and Metabolic control among Adult Subjects with Symptomatic Hypoparathyroidism Treated with Recombinant Human Parathyroid hormone [rhPTH(1-84)] | A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)] | Hypoparathyroidism MedDRA version: 20.0 Level: PT Classification code 10051315 Term: Congenital hypoparathyroidism System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0 Level: PT Classification code 10075900 Term: Primary hypoparathyroidism System Organ Class: 10014698 - Endocrine disorders MedDRA version: 20.0 Level: PT Classification code 10021041 Term: Hypoparathyroidism System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Body processes [G] - Biological Phenomena [G16] | Trade Name: Natpara Product Name: human recombinant parathyroid hormone Product Code: rhPTH(1-84) Pharmaceutical Form: Lyophilisate and solvent for solution for injection INN or Proposed INN: RECOMBINANT HUMAN PARATHYROID HORMONE (1-84) CAS Number: 9002-64-6 Current Sponsor code: SHP634 Other descriptive name: Parathyroid Hormone Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Lyophilisate and solvent for solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Natpara Product Name: human recombinant parathyroid hormone Product Code: rhPTH(1-84) Pharmaceutical Form: Lyophilisate and solvent for solution for injection INN or Proposed INN: RECOMBINANT HUMAN PARATHYROID HORMONE (1-84) CAS Number: 9002-64-6 Current Sponsor code: SHP634 Other descriptive name: Parathyroid Hormone Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Lyophilisate and solvent for solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Natpara Product Name: human recombinant parathyroid hormone Product Code: rhPTH(1-84) Pharmaceutical Form: Lyophilisate and solvent for solution for injection INN or Proposed INN: RECOMBINANT HUMAN PARATHYROID HORMONE (1-84) CAS Number: 9002-64-6 Current Sponsor code: SHP634 | Shire Human Genetic Therapies, Inc. | Authorised | Female: yes Male: yes | 150 | Phase 3;Phase 4 | Portugal;France;United States;Belgium;Spain;Denmark;Norway;Netherlands;Germany;Italy;United Kingdom;Sweden | |||
| 9 | EUCTR2017-000284-32-DK | 10/01/2018 | 28 February 2019 | Symptom Improvement Evaluation and Metabolic control among Adult Subjects with Symptomatic Hypoparathyroidism Treated with Recombinant Human Parathyroid hormone [rhPTH(1-84)] | A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)] | Hypoparathyroidism MedDRA version: 20.0 Level: PT Classification code 10051315 Term: Congenital hypoparathyroidism System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0 Level: PT Classification code 10075900 Term: Primary hypoparathyroidism System Organ Class: 10014698 - Endocrine disorders MedDRA version: 20.0 Level: PT Classification code 10021041 Term: Hypoparathyroidism System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Body processes [G] - Biological Phenomena [G16] | Trade Name: Natpara Product Name: human recombinant parathyroid hormone Product Code: rhPTH(1-84) Pharmaceutical Form: Lyophilisate and solvent for solution for injection INN or Proposed INN: RECOMBINANT HUMAN PARATHYROID HORMONE (1-84) CAS Number: 9002-64-6 Current Sponsor code: SHP634 Other descriptive name: Parathyroid Hormone Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Lyophilisate and solvent for solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Natpara Product Name: human recombinant parathyroid hormone Product Code: rhPTH(1-84) Pharmaceutical Form: Lyophilisate and solvent for solution for injection INN or Proposed INN: RECOMBINANT HUMAN PARATHYROID HORMONE (1-84) CAS Number: 9002-64-6 Current Sponsor code: SHP634 Other descriptive name: Parathyroid Hormone Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Lyophilisate and solvent for solution for injection Route of administration of the placebo: Subcutaneous use Trade Name: Natpara Product Name: human recombinant parathyroid hormone Product Code: rhPTH(1-84) Pharmaceutical Form: Lyophilisate and solvent for solution for injection INN or Proposed INN: RECOMBINANT HUMAN PARATHYROID HORMONE (1-84) CAS Number: 9002-64-6 Current Sponsor code: SHP634 | Shire Human Genetic Therapies, Inc. | Authorised | Female: yes Male: yes | 150 | Phase 3;Phase 4 | Portugal;France;United States;Belgium;Spain;Denmark;Norway;Netherlands;Germany;Italy;United Kingdom;Sweden | |||
| 10 | NCT03249012 | September 1, 2017 | 11 February 2019 | Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy Hypoparathyroidism | Comparing the Quality of Life Associated With Empiric Calcium Repletion and Parathormone (PTH) Based Calcium Repletion for Post Thyroidectomy Hypoparathyroidism | Hypoparathyroidism Postprocedural;Quality of Life | Other: Empiric use of Calcium Carbonate and Calcitriol;Other: PTH based Calcium Carbonate and Calcitriol repletion | CHU de Quebec-Universite Laval | Recruiting | 18 Years | N/A | All | 120 | N/A | Canada | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT02824718 | June 6, 2017 | 7 October 2019 | Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism | A Randomized Crossover TrIal to Compare Recombinant Human rhPTH(1-34) to the ASsociation Alfacalcidol/Hydrochlorothiazide in the Treatment of Severe Primary Hypoparathyroidism | Autosomal Dominant Hypocalcemia or OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment | Drug: Teriparatide;Drug: Thiazide;Drug: Potassium sparing diuretic;Drug: Alfacalcidol | Assistance Publique - Hôpitaux de Paris | Ministry of Health, France | Recruiting | 18 Years | 80 Years | All | 12 | Phase 2 | France |
| 12 | NCT03150108 | May 16, 2017 | 16 December 2017 | Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects | A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of rhPTH(1-84) Administered Subcutaneously in Japanese Healthy Subjects Compared With Matched Non-Hispanic, Caucasian Healthy Adult Subjects and to Assess Dose Proportionality of 3 Doses of rhPTH(1-84) in the Japanese Subjects | Hypoparathyroidism | Drug: rhPTH(1-84) | Shire | Not recruiting | 18 Years | 65 Years | All | 24 | Phase 1 | United States | |
| 13 | NCT02781844 | March 11, 2017 | 8 April 2019 | Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism | An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects With Hypoparathyroidism | Hypoparathyroidism | Drug: 25mcg rhPTH(1-84);Drug: 50mcg rhPTH(1-84);Drug: 100mcg rhPTH(1-84) | Shire | Not recruiting | 18 Years | N/A | All | 33 | Phase 1 | United States;Canada;Denmark;Hungary | |
| 14 | NCT04146259 | January 1, 2017 | 11 November 2019 | Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism | Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism | Hypoparathyroidism Postprocedural | Drug: calcium carbonate and alphacalcidol | University of Athens | Not recruiting | 19 Years | N/A | Female | 109 | Phase 4 | Greece | |
| 15 | NCT02910466 | December 9, 2016 | 20 May 2019 | A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism | A Phase 4, Open-Label, Single-Center Clinical Study of Extended Use of rhPTH(1-84) in Hypoparathyroidism | Chronic Hypoparathyroidism;Hypoparathyroidism | Drug: rhPTH(1-84) | Shire | Not recruiting | 18 Years | 85 Years | All | 50 | Phase 4 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT04012476 | November 2016 | 22 July 2019 | Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy | Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy | Hypocalcemia;Total Thyroidectomy;Hypoparathyroidism Postprocedural | Drug: Indocyanine Green | Hospital Son Espases | Universitat de les Illes Balears | Recruiting | 18 Years | N/A | All | 40 | Phase 4 | Spain |
| 17 | NCT02986607 | March 2016 | 16 December 2017 | Corticosteroid Rhythms in Hypoparathyroid Patients | Corticosteroid Rhythms in Hypoparathyroid Patients | Hypoparathyroidism;Hyperparathyroidism | Drug: parathyroid hormon 1-84 | University of Bergen | Haukeland University Hospital | Recruiting | 18 Years | 60 Years | All | 30 | Early Phase 1 | Norway |
| 18 | NCT02652884 | January 2016 | 18 April 2016 | Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy | Evaluation of Potential Benefits of Using Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy | Transient Hypoparathyroidism | Drug: phosphate and betamethasone acetate, 2 mL.;Drug: saline 0.9% NaCl | Hospital Italiano de Buenos Aires | Recruiting | 18 Years | N/A | Both | 110 | Phase 4 | Argentina | |
| 19 | EUCTR2015-003108-22-GB | 08/12/2015 | 25 April 2016 | Study on parathyroid hormone for use in hypoparathyroidism in children 12 to less than 18 years old. | An Open-label, Single-dose Study to Determine the Pharmacokinetic/Pharmacodynamic Profile of Parathyroid Hormone (rDNA) Administered Subcutaneously at a Dose of 50 µg in Subjects with Hypoparathyroidism Who Are 12 to Less Than 18 Years of Age | Chronic hypoparathyroidism;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Product Name: Parathyroid Hormone (rDNA) Product Code: NPSP 558 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: INN Parathyroid Hormone (1-84) human CAS Number: 68893-82-3 Current Sponsor code: NPSP 558 Other descriptive name: Parathyroid Hormone (1-84) Human Recombinant Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 50- | NPS Pharmaceuticals, Inc. | Authorised | Female: yes Male: yes | 10 | United Kingdom | ||||
| 20 | NCT02152228 | July 2014 | 19 October 2015 | A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism | A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism | Hypoparathyroidism | Drug: EnteraBio's Oral Parathyroid Hormone (1-34) | Entera Bio Ltd. | Not recruiting | 18 Years | 80 Years | Both | 20 | Phase 2 | Israel | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | EUCTR2013-001890-26-IT | 06/05/2014 | 26 February 2018 | Recombinant human parathyroid hormone [rh PTH(1-34): Teriparatide] as therapy for refractory hypoparathyroidism | Recombinant human parathyroid hormone [rh PTH(1-34): Teriparatide] as therapy for refractory hypoparathyroidism | Refractory hypoparathyroidism MedDRA version: 16.1 Level: PT Classification code 10021041 Term: Hypoparathyroidism System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: FORSTEO Product Name: FORSTEO Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: TERIPARATIDE CAS Number: 52232-67-4 Concentration unit: µg/µl microgram(s)/microlitre Concentration type: range Concentration number: 20-40 | Dipartimento di Medicina e Chirurgia Traslazionale dell’Università degli Studi di Firenze | Authorised | Female: yes Male: yes | 30 | Phase 3 | Italy | |||
| 22 | NCT01922440 | July 1, 2013 | 15 July 2019 | A Registry for Patients With Chronic Hypoparathyroidism | PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism | Chronic Hypoparathyroidism | Drug: Combination product (Natpara) and drug or supplements [Disease and drug registry] | Shire | Recruiting | N/A | N/A | All | 900 | Phase 1 | United States;Austria;Canada;Denmark;Germany;Norway;Sweden | |
| 23 | NCT01815021 | April 2013 | 13 April 2015 | A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients | A Randomized, Two Phase, Adaptive Then Crossover Open-label, Study Comparing Amorphous Calcium Carbonate (ACC) Supplement Versus Commercially Available Crystalline Calcium Supplements (CCS) in the Management of Primary Hypoparathyroidism. | Hypoparathyroidism | Dietary Supplement: amorphous calcium carbonate;Dietary Supplement: crystalline calcium supplements | Amorphical Ltd. | Not recruiting | 18 Years | 80 Years | Both | 10 | Phase 1/Phase 2 | Israel | |
| 24 | NCT02924532 | February 2012 | 17 October 2016 | Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy | Diagnostic Value of Immediate Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy: A Retrospective Observational Study | Hypoparathyroidism | Biological: immediate post operative bioassay of Parathyroid Hormone | Centre Hospitalier Universitaire de Nimes | Not recruiting | 18 Years | N/A | Both | 300 | N/A | ||
| 25 | NCT01455181 | August 2011 | 19 October 2017 | A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary | A 6-Month Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study | Hypoparathyroidism | Drug: NPSP558 | Shire | Not recruiting | 18 Years | 85 Years | All | 24 | Phase 3 | Hungary | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | EUCTR2011-001265-40-HU | 29/07/2011 | 12 November 2012 | A Study to Assess the Effects of Parathyroid Hormone (rhPTH [1-84]), in Submjects with Hypoparathyroidism | A 6-Month Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults with Hypoparathyroidism - A Clinical Extension Study - Not applicable | Hypoparathyroidism MedDRA version: 13.1 Level: PT Classification code 10021041 Term: Hypoparathyroidism System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: PREOTACT Product Name: Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Product Code: NPSP 558 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Parathyroid Hormone CAS Number: 68893-82-3 Current Sponsor code: NPSP 558 Other descriptive name: PARATHYROID HORMONE Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 50- Trade Name: PREOTACT Product Name: Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Product Code: NPSP 558 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Parathyroid Hormone CAS Number: 68893-82-3 Current Sponsor code: NPSP 558 Other descriptive name: PARATHYROID HORMONE Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 75- Trade Name: PREOTACT Product Name: Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Product Code: NPSP 558 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Parathyroid Hormone CAS Number: 68893-82-3 Current Sponsor code: NPSP 558 Other descriptive name: PARATHYROID HORMONE Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 100- | NPS Pharmaceuticals, Inc. | Not Recruiting | Female: yes Male: yes | 30 | Hungary | ||||
| 27 | NCT01297309 | April 1, 2011 | 27 August 2018 | A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE) | A Long-term Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE) | Hypoparathyroidism | Drug: NPSP558 | Shire | Not recruiting | 18 Years | 85 Years | All | 53 | Phase 3 | United States | |
| 28 | NCT01268098 | January 2011 | 19 October 2017 | Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY) | A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism | Hypoparathyroidism | Drug: NPSP558 | Shire | Not recruiting | 18 Years | 85 Years | All | 42 | Phase 3 | United States | |
| 29 | NCT01171690 | November 2010 | 19 October 2017 | Teriparatide for Postsurgical Hypoparathyroidism | Pilot Study of Teriparatide for Postsurgical Hypoparathyroidism | Hypoparathyroidism Post-surgical | Drug: Teriparatide | Mayo Clinic | Not recruiting | 18 Years | 80 Years | All | 5 | Phase 2 | United States | |
| 30 | NCT00856401 | September 2010 | 12 March 2018 | ADD-ON Study to Existing Hypoparathyroidism Studies | Phase II Trial of Parathyroid Hormone for the Treatment of Hypoparathyroidism | Hypoparathyroidism | Drug: PTH1-84 in parent study | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 18 Years | 85 Years | All | 62 | Phase 3 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT01199614 | December 2009 | 20 August 2018 | HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism | HEXT: The Hypoparathyroidism Studies, EXTended: The Effect of PTH on the Skeleton in Hypoparathyroidism | Hypoparathyroidism | Drug: open-label PTH(1-84) | John P. Bilezikian | NPS Pharma;Shire | Not recruiting | 18 Years | 85 Years | All | 75 | Phase 3 | United States |
| 32 | EUCTR2008-005063-34-FR | 14/09/2009 | 28 August 2012 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP 558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)] for the Treatment of Adults with Hypoparathyroidism - Not applicable | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP 558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)] for the Treatment of Adults with Hypoparathyroidism - Not applicable | Hypoparathyroidism MedDRA version: 9.1 Level: LLT Classification code 10021041 Term: Hypoparathyroidism | Product Name: Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Product Code: NPSP 558 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Parathyroid Hormone CAS Number: 68893-82-3 Current Sponsor code: NPSP 558 Other descriptive name: PARATHYROID HORMONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.61- Pharmaceutical form of the placebo: Powder and solvent for solution for injection Route of administration of the placebo: Subcutaneous use Product Name: Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Product Code: NPSP 558 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Parathyroid Hormone CAS Number: 68893-82-3 Current Sponsor code: NPSP 558 Other descriptive name: PARATHYROID HORMONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.20- Pharmaceutical form of the placebo: Powder and solvent for solution for injection Route of administration of the placebo: Subcutaneous use Product Name: Rcombinant Human Parathyroid Hormone [rhPTH(1-84)] Product Code: NPSP 558 Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: Parathyroid Hormone CAS Number: 68893-82-3 Current Sponsor code: NPSP 558 Other descriptive name: PARATHYROID HORMONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.80- Pharmaceutical form of the placebo: Powder and solvent for solution for injection Route of administration of the placebo: Subcutaneous use | NPS Pharmaceuticals, Inc. | Authorised | Female: yes Male: yes | 84 | Phase 3 | Hungary;United Kingdom;Belgium;Denmark;France;Italy;Lithuania | |||
| 33 | JPRN-UMIN000002155 | 2009/09/01 | 2 April 2019 | Effects of falecalcitoriol on post-operative hypoparathyroidism after thyroidectomy | Postoperative hypoparathyroidism | In the first day after operation, we start administration of falecalcitriol at a dosage of 0.6ug once a day, when below the lower limit of serum calcium. If serum calcium level do not reach normal range, we escalete to 0.9ug/day.Oral calcium lactate is administered 3g/day in all enrolled patients.The dose is reduced when serum calcium and intact PTH level are maintained within normal range. If subjective symptoms such as tetany are worsen up, we start administration of calcium via DIV. | kawasaki medicak school | Not Recruiting | Not applicable | Not applicable | Male and Female | 30 | Phase 3 | Japan | ||
| 34 | NCT00824226 | January 2009 | 19 February 2015 | Magnesium Treatment in Hypoparathyroidism | Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients | Hypoparathyroidism | Dietary Supplement: magnesium | University of Tartu | Not recruiting | 18 Years | N/A | Both | 10 | N/A | Estonia | |
| 35 | NCT00732615 | December 2008 | 19 October 2017 | Use of NPSP558 in the Treatment of Hypoparathyroidism | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Investigate the Use of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH[1-84]) for the Treatment of Adults With Hypoparathyroidism | Hypoparathyroidism | Drug: Placebo;Drug: NPSP558 | Shire | Not recruiting | 18 Years | 85 Years | All | 124 | Phase 3 | United States;Belgium;Canada;Denmark;France;Hungary;Italy;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT00743782 | August 22, 2008 | 11 November 2019 | Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism | Comparing Pump vs. Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism | Hypoparathyroidism;Hypocalcemia | Drug: Synthetic Human Parathyroid Hormone 1-34 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Not recruiting | 7 Years | 70 Years | All | 24 | Early Phase 1 | United States | |
| 37 | NCT00730210 | June 2008 | 19 February 2015 | Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life | Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life | Hypoparathyroidism | Drug: a: PTH (1-84);Drug: b:placebo | University of Aarhus | Not recruiting | 25 Years | 80 Years | Both | 62 | Phase 2 | Denmark | |
| 38 | EUCTR2008-000606-36-DK | 07/04/2008 | 19 March 2012 | Treatment of hypoparathyroidism with subcutaneous PTH (1-84) injections: effects on muscle function and quality of life - HypoPT | Treatment of hypoparathyroidism with subcutaneous PTH (1-84) injections: effects on muscle function and quality of life - HypoPT | Hypoparathyroidism MedDRA version: 9.1 Level: LLT Classification code 10021041 Term: Hypoparathyroidism | Trade Name: Preotact Product Name: parathyroid hormone (rdna) Product Code: SUB21634 Pharmaceutical Form: Solution for injection INN or Proposed INN: Parathyroideahormon Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Subcutaneous use | Aarhus University Hospital, Dept of Endocrinology and Metabolism C | Not Recruiting | Female: yes Male: yes | 60 | Denmark | ||||
| 39 | NCT00395538 | October 30, 2006 | 2 September 2019 | Effects of PTH Replacement on Bone in Hypoparathyroidism | Effects of PTH Replacement on Bone in Hypoparathyroidism | Hypoparathyroidism;DiGeorge Syndrome | Drug: PTH 1-34 | National Institute of Dental and Craniofacial Research (NIDCR) | Not recruiting | 18 Years | 70 Years | All | 46 | Phase 3 | United States;Austria;Italy | |
| 40 | JPRN-UMIN000000475 | 2006/07/01 | 2 April 2019 | Therapeutic strategy of relative hypoparathyroidism in hemodialysis patients using sevelamer hydrochloride, with special reference to vitamin D administration | Relative hypoparathyoidism in maintenance hemodialysis patients | Replacement of calcium carbonate with sevelamer hydrochloride as phosphate binder | Hokusetsu ROD Study Group | Not Recruiting | 20years-old | Not applicable | Male and Female | 40 | Not applicable | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT00566488 | January 2005 | 20 May 2019 | Parathyroid and Thymus Transplantation in DiGeorge #931 | Parathyroid and Thymus Transplantation in DiGeorge Syndrome, #931 | DiGeorge Syndrome;Hypoparathyroidism;Complete DiGeorge Syndrome | Biological: Thymus/Parathyroid Transplantation | M. Louise Markert | Food and Drug Administration (FDA);National Institutes of Health (NIH);National Institute of Allergy and Infectious Diseases (NIAID);Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);Enzyvant Therapeutics GmbH | Not recruiting | N/A | 24 Months | All | 25 | Phase 1 | United States |
| 42 | NCT00581828 | January 2005 | 19 October 2017 | Does Treatment of Hypovitaminosis D Increase Calcium Absorption? | Does Treatment of Hypovitaminosis D Increase Calcium Absorption? | Osteoporosis;Osteopenia;Vitamin D Deficiency;Hypoparathyroidism;Hypercalciuria;Hypercalcemia | Drug: Vitamin D | University of Wisconsin, Madison | Not recruiting | N/A | N/A | Female | 19 | Phase 4 | United States | |
| 43 | NCT00004361 | July 1995 | 19 February 2015 | Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects | Hypoparathyroidism;Tetralogy of Fallot;Pulmonary Valve Stenosis;Conotruncal Cardiac Defects;Heart Defects, Congenital;Pulmonary Atresia | Drug: calcium gluconate;Drug: sodium citrate | National Center for Research Resources (NCRR) | Ann & Robert H Lurie Children's Hospital of Chicago | Not recruiting | 18 Years | N/A | Both | 150 | N/A | ||
| 44 | NCT00001304 | October 1991 | 19 October 2017 | Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34 | Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34 | Hypoparathyroidism | Drug: Synthetic Human Parathyroid Hormone 1-34;Drug: Calcitriol & Calcium | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Not recruiting | 17 Years | 69 Years | All | 27 | Phase 2 | United States |